Screening of plant derived chalcones on the inhibition of potato apyrase: Potential protein biotechnological applications in health

In vivo efficacy of uvangoletin from Piper aduncum (Piperaceae) against Schistosoma mansoni and in silico studies targeting SmNTPDases

Schistosomiasis stands as one of the most significant parasitic diseases on a global scale, with approximately 250 million infections worldwide. It is imperative to address this pressing issue by developing new antischistosomal drugs. Chalcones have emerged as a promising class of natural compounds, demonstrating noteworthy effects observed in vitro experiments with Schistosoma mansoni, and demonstrating the ability to inhibit SmNTPDases and apyrase from potatoes. In this study, we focused on uvangoletin, a naturally occurring dihydrochalcone from Piper aduncum. We isolated uvangoletin from P. aduncum fruits and conducted in vivo experiments to evaluate the efficacy of uvangoletin against adult Schistosoma parasites. Furthermore, we explored the inhibitory effects of uvangoletin on potato apyrase and employed molecular docking analyses to investigate its interactions with apyrase from potato and the two isoforms SmNTPDase 1 and 2 through in silico studies. Uvangoletin (400 mg/kg, p. o.), exhibited significant in vivo antiparasitic effects against adult S. mansoni, leading to a decrease of 53.7% in worm burden and 54.3% in egg production. The treatment also reduced hepatomegaly and splenomegaly. In silico investigations and ADMET studies indicated that uvangoletin possesses favorable drug-like properties and may interact with key residues involved in apyrase and SmNTPDases activities. Furthermore, uvangoletin demonstrated a substantial reduction in potato apyrase activity. These results suggest the potential for exploring other dihydrochalcones as promising candidates for antischistosomal agents.

Extracellular AMP Inhibits Pollen Tube Growth in Picea meyeri via Disrupted Calcium Gradient and Disorganized Microfilaments

Adenosine monophosphate (AMP) is a hydrolysis product of adenosine triphosphate (ATP) and adenosine diphosphate (ADP). In mammalian cells, extracellular AMP functions as a signaling molecule by binding to adenosine A1 receptors, thereby activating various intracellular signaling pathways. However, the role of extracellular AMP in plant cells remains largely unclear, and homologs of A1 receptors have not been identified. Our previous studies have demonstrated that extracellular ATP (eATP) is crucial for the normal germination and growth of Picea meyeri pollen tubes. In the present study, we observed that the exogenous addition of ATP to a pollen culture medium could be degraded into AMP and adenosine. Furthermore, the addition of AMP and adenosine to the culture medium was found to inhibit pollen germination and tube elongation. Notably, the addition of an AMP receptor inhibitor into the culture medium mitigated the inhibitory effects of AMP on pollen tube growth. Through intracellular staining for Ca2+ and microfilaments, we discovered that high concentrations of AMP disrupt the Ca2+ concentration gradient and impair microfilament organization, ultimately resulting in inhibited pollen tube elongation. In conclusion, we propose that extracellular AMP, as a hydrolysis product of eATP, also plays a significant role in regulating P. meyeri pollen germination and tube growth in vitro.

Ectonucleotidase inhibitors: an updated patent review (2017-2023)

INTRODUCTION

The main enzymes that hydrolyzes nucleotides at the cell surface are nucleoside triphosphate diphosphohydrolases (NTPDases), ecto-nucleotide pyrophosphatases/phosphodiesterases (ENPPs), alkaline phosphatases (APs) and ecto-5'- nucleotidase (e5'NT, CD73) and by regulating the concentration of nucleotides at the cell surface, these enzymes have the potential to affect various conditions such as fibrosis, cancer metastasis, pruritus, inflammation, and autoimmune diseases. Thus, they represent a prospective therapeutic target.

AREA COVERED

A number of molecules, including nucleoside/nucleotide and non-nucleoside analogues, and bicyclic compounds, have shown strong potential as ectonucleotidase inhibitors. This review covers the chemistry and clinical uses of ectonucleotidase inhibitors patented between 2017 and 2023.

EXPERT OPINION

By binding to their specific P1 and P2 receptors at the cell surface, nucleosides and nucleotides regulate a number of pathophysiological events such as inflammation, fibrosis, cancer, and autoimmune diseases. Interestingly, these nucleotides can be hydrolyzed to nucleosides by several cell surface enzymes called ectonucleotidases. The development of small molecules that modulate ectonucleotidase activity is, therefore, of therapeutic value. This review provides valuable insights into recent advancements, including combination therapy and enhanced selectivity, which are poised to shape the future of ectonucleotidase inhibition through a comprehensive analysis of patents.

Identification of Asiaticoside from Centella erecta (Apiaceae) as Potential Apyrase Inhibitor by UF-UHPLC-MS and Its In Vivo Antischistosomal Activity

Schistosomiasis, caused by parasites of the genus Schistosoma, is a neglected disease with high global prevalence, affecting more than 240 million people in several countries. Praziquantel (PZQ) is the only drug currently available for the treatment. S. mansoni NTPDases (known as SmNTPDases, ATP diphosphohydrolases or ecto-apyrases) are potential drug targets for the discovery of new antischistosomal drugs. In this study, we screen NTPDases inhibitors from Centella erecta (Apiaceae) using an ultrafiltration combined UHPLC-QTOF-MS method and potato apyrase, identifying asiaticoside as one of the apyrase-binding compounds. After isolation of asiaticoside from C. erecta extract, we assessed its in vivo antischistosomal activities against Schistosoma mansoni worms and its in vitro enzymatic apyrase inhibition. Also, molecular docking analysis of asiaticoside against potato apyrase, S. mansoni NTPDases 1 and 2 were performed. Asiaticoside showed a significant in vitro apyrase inhibition and molecular docking studies corroborate with its possible actions in potato apyrase and S. mansoni NTPDases. In mice harboring a patent S. mansoni infection, a single oral dose of asiaticoside (400 mg/kg. p.o.) showed significantly in vivo antischistosomal efficacy, markedly decreasing the total worm load and egg burden, giving support for further exploration of apyrase inhibitors as antischistosomal agents.

Synthetic Aurones: New Features for Schistosoma mansoni Therapy

In this work, two synthetic aurones revealed moderate schistosomicidal potential in in vitro and in vivo assays. Aurones (1) and (2) promoted changes in tegument integrity and motor activity, leading to death of adult Schistosoma mansoni worms in in vitro assays. When administered orally (two doses of 50 mg/kg) in experimentally infected animals, synthetic aurones (1) and (2) promoted reductions of 56.20 % and 57.61 % of the parasite load and stimulated the displacement towards the liver of the remaining adult worms. The oogram analysis revealed that the treatment with both aurones interferes with the egg development kinetics in the intestinal tissue. Seeking an action target for compounds (1) and (2), the connection with NTPDases enzymes, recognized as important therapeutic targets for S. mansoni, was evaluated. Molecular docking studies have shown promising results. The dataset reveals the anthelmintic character of these compounds, which can be used in the development of new therapies for schistosomiasis.

Cardamonin Presents in Vivo Activity against Schistosoma mansoni and Inhibits Potato Apyrase

Schistosomiasis, a neglected tropical disease caused by Schistosoma species, harms over 250 million people in several countries. The treatment is achieved with only one drug, praziquantel. Cardamonin, a natural chalcone with in vitro schistosomicidal activity, has not been in vivo evaluated against Schistosoma. In this work, we evaluated the in vivo schistosomicidal activities of cardamonin against Schistosoma mansoni worms and conducted enzymatic apyrase inhibition assay, as well as molecular docking analysis of cardamonin against potato apyrase, S. mansoni NTPDase 1 and S. mansoni NTPDase 2. In a mouse model of schistosomiasis, the oral treatment with cardamonin (400 mg/kg) showed efficacy against S. mansoni, decreasing the total worm load in 46.8 % and reducing in 54.5 % the number of eggs in mice. Cardamonin achieved a significant inhibition of the apyrase activity and the three-dimensional structure of the potato apyrase, obtained by homology modeling, showed that cardamonin may interact mainly through hydrogen bonds. Molecular docking studies corroborate with the action of cardamonin in binding and inhibiting both potato apyrase and S. mansoni NTPDases.

Recent Advances Clarifying the Structure and Function of Plant Apyrases (Nucleoside Triphosphate Diphosphohydrolases)

Studies implicating an important role for apyrase (NTPDase) enzymes in plant growth and development began appearing in the literature more than three decades ago. After early studies primarily in potato, Arabidopsis and legumes, especially important discoveries that advanced an understanding of the biochemistry, structure and function of these enzymes have been published in the last half-dozen years, revealing that they carry out key functions in diverse other plants. These recent discoveries about plant apyrases include, among others, novel findings on its crystal structures, its biochemistry, its roles in plant stress responses and its induction of major changes in gene expression when its expression is suppressed or enhanced. This review will describe and discuss these recent advances and the major questions about plant apyrases that remain unanswered.